Particle Size Distribution (PSD) Method Validation Using Malvern Mastersizer 3000 for Drug Substance and Drug Product: A Risk-Based Regulatory Lifecycle Approach
Particle Size Distribution (PSD) is a critical quality attribute (CQA) for a wide range of pharmaceutical drug substances and drug products, directly influencing dissolution, bioavailability, blend and content uniformity, stability, and manufacturability. Laser diffraction has become the compendial and industrial standard for PSD analysis, with the Malvern Mastersizer 3000 widely used in pharmaceutical development and quality control laboratories. However, regulatory inspections continue to identify deficiencies related to dispersion optimization, method validation, sampling representativeness, and lifecycle management of PSD methods. This study presents a comprehensive evaluation of PSD method validation using both dry and wet dispersion accessories of the Malvern Mastersizer 3000, specifically the Aero S (dry dispersion) and Hydro MV (wet dispersion) systems. Experimental datasets generated during method development and validation were used to evaluate measurement performance for two representative pharmaceutical materials: Drug substance and Drug product. Key PSD parameters, including D10, D50, and D90, were assessed under optimized dispersion conditions. Method validation parameters such as repeatability, intermediate precision, and robustness were evaluated using risk-based analytical validation principles aligned with ICH Q2 (R2). The study is further contextualized within the integrated pharmaceutical quality framework described in ICH Q7-Q11, linking PSD measurement to drug substance characterization, process understanding, and lifecycle management. The findings demonstrate that appropriate dispersion selection and statistically justified validation are essential for ensuring reliable PSD control. Overall, PSD measurement should be viewed not merely as an analytical test but as a critical tool for process understanding and quality control within modern pharmaceutical manufacturing systems. This article reviews the scientific and regulatory basis of laser-diffraction PSD testing and presents a case study validating dry and wet Mastersizer 3000 methods for a drug substance powder and a cream drug product. The study applies dispersion optimization, sampling controls, and precision, intermediate precision, and robustness assessments within an ICH Q2 (R2)-aligned framework. The main conclusion is that material-specific dispersion selection and lifecycle-based validation are necessary for reliable PSD control.
References
[1]
Chu, K.R., Lee, E., Jeong, S.H. and Park, E. (2012) Effect of Particle Size on the Dissolution Behaviors of Poorly Water-Soluble Drugs. ArchivesofPharmacalResearch, 35, 1187-1195. https://doi.org/10.1007/s12272-012-0709-3
[2]
Zheng, K., Lin, Z., Capece, M., Kunnath, K., Chen, L. and Davé, R.N. (2019) Effect of Particle Size and Polymer Loading on Dissolution Behavior of Amorphous Griseofulvin Powder. JournalofPharmaceuticalSciences, 108, 234-242. https://doi.org/10.1016/j.xphs.2018.11.025
[3]
Wilson, D., Crampton, A., Sullivan, R. and Liljeblad, A. (2022) An Analysis of the Technical and Economic Influences of Particle Size Control of an Active Pharmaceutical Ingredient. JournalofPharmaceuticalInnovation, 17, 501-509. https://doi.org/10.1007/s12247-020-09526-1
[4]
Liu, L.X., Marziano, I., Bentham, A.C., Litster, J.D., White, E.T. and Howes, T. (2008) Effect of Particle Properties on the Flowability of Ibuprofen Powders. InternationalJournalofPharmaceutics, 362, 109-117. https://doi.org/10.1016/j.ijpharm.2008.06.023
[5]
Sun, Z., Ya, N., Adams, R.C. and Fang, F.S. (2010) Particle Size Specifications for Solid Oral Dosage Forms: A Regulatory Perspective. American Pharmaceutical Re-view, 13, 68-73. https://www.americanpharmaceuticalreview.com/Featured-Articles/36779-Particle-Size-Specifications-for-Solid-Oral-Dosage-Forms-A-Regulatory-Perspective/
[6]
Snorek, S.M., Bauer, J.F., Chidambaram, N., Doub, W.H., Duffy, E.P., Etzler, F.M., et al. (2007) PQRI Recommendations on Particle-Size Analysis of Drug Substances Used in Oral Dosage Forms. Journal of Pharmaceutical Sciences, 96, 1451-1467.
[7]
United States Pharmacopeia (USP) (2025) USP <429> Light Diffraction Measurement of Particle Size. United States Pharmacopeial Convention.
[8]
Shekunov, B.Y., Chattopadhyay, P., Tong, H.H.Y. and Chow, A.H.L. (2007) Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications. PharmaceuticalResearch, 24, 203-227. https://doi.org/10.1007/s11095-006-9146-7
[9]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2000) ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH.
[10]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2009) ICH Q8 (R2): Pharmaceutical Development. ICH.
[11]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2023) ICH Q9 (R1): Quality Risk Management. ICH.
[12]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2008) ICH Q10: Pharmaceutical Quality System. ICH.
[13]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2012) ICH Q11: Development and Manufacture of Drug Substances (Chemical and Biotechnological/Biological Entities). ICH.
[14]
US Food and Drug Administration, Guidance for Industry (2022) Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs, Guidance for Industry. https://www.fda.gov/media/162471/download
[15]
Chiarentin, L., Moura, V., Major, F., Catita, J., Miranda, M. and Vitorino, C. (2025) Particle Size by Design: Standardizing Measurements for Complex Topical Drug Product Assessment. ColloidsandSurfacesA: PhysicochemicalandEngineeringAspects, 705, Article ID: 135679. https://doi.org/10.1016/j.colsurfa.2024.135679
[16]
Barber, D., Keuter, J. and Kravig, K. (1998) A Logical Stepwise Approach to Laser Diffraction Particle Size Distribution Analysis Methods Development and Validation. PharmaceuticalDevelopmentandTechnology, 3, 153-161. https://doi.org/10.3109/10837459809028491
[17]
Dubey, J., Rajyaguru, B., Vankawala, K., Vaidya, F., Mistri, J. and Surati, K. (2025) Development and Validation of New Analytical Method for the Determination of Particle Size Distribution in Empagliflozin Using Laser-Based Particle Size Analyzer. JournalofAdvancesinMedicalandPharmaceuticalSciences, 27, 65-74. https://doi.org/10.9734/jamps/2025/v27i11828
[18]
Medendorp, J., Bric, J., Connelly, G., Tolton, K. and Warman, M. (2015) Development and Beyond: Strategy for Long-Term Maintenance of an Online Laser Diffraction Particle Size Method in a Spray Drying Manufacturing Process. JournalofPharmaceuticalandBiomedicalAnalysis, 112, 79-84. https://doi.org/10.1016/j.jpba.2015.04.019
[19]
Nataraj, P., Ravisankar, M., Vijayakumar, M., Sivagamy, M. and Senthilkumar, G.P. (2025) Analytical Method Development and Validation to Assess the Particle Size Distribution in Azithromycin Oral Suspension 200 mg/5 ml. SaudiJournalofMedicalandPharmaceuticalSciences, 11, 949-952. https://doi.org/10.36348/sjmps.2025.v11i10.004
[20]
Pearson, J., Nguyen, T.L., C？lfen, H. and Mulvaney, P. (2018) Sedimentation of C60 and C70: Testing the Limits of Stokes’ Law. TheJournalofPhysicalChemistryLetters, 9, 6345-6349. https://doi.org/10.1021/acs.jpclett.8b02703
[21]
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2023) ICH Q2 (R2): Validation of Analytical Procedures. ICH. (Revised Guideline Adopted November 2023)
[22]
Gosar, A., Jadhav, S., Lalge, A. and Patil, M. (2020) Development and Validation of Novel Analytical Method for the Determination of Particle Size Distribution in Lumefantrine Using Laser-Based Particle Size Analyzer. Indo American Journal of Pharmaceutical Research, 11, 1457-1465.
[23]
Gosar, A., Parange, C., Narvankar, S., Jadhav, S. and Patil, V. (2022) Development and Validation of Novel Analytical Method for the Determination of Particle Size Distribution in Ciprofloxacin Hydrochloride Using Laser-Based Particle Size Analyzer. Journalof Advances in Medical and Pharmaceutical Sciences, 24, 40-47. https://doi.org/10.9734/jamps/2022/v24i730316
[24]
Xie, L., Su, L., Xiao, Y., Zhang, R.-Q. and Zheng, P. (2024) Determination of Particle Size Distribution of Budesonide Suspension for Inhalation by Laser Diffraction Method. Chinese Journal of Pharmaceutical Analysis, 44, 2004-2010. (In Chinese)
[25]
Guo, B., Hao, G., Qian, X., Pan, X.-W. and Chen, R. (2021) Establishment and Validation of Particle Size Distribution Determination Method of Rivaroxaban by Laser Light Scattering. Chinese Journal of Pharmaceutical Analysis, 41, 1649-1654. (In Chinese)
[26]
Wang, Y., Wu, S., Xue, D., Zhang, K., Shao, H., Xu, W., Zhang, D., Zhang, S. and Yang, Q.-Y. (2021) Methodological Study of Particle Size Distribution of Bromhexine Hydrochloride by Laser Diffraction Method. Chinese Journal of Pharmaceutical Analysis, 41, 1448-1453. (In Chinese)
[27]
Cheng, D., Xue, M., Yin, J., Qiu, X., Liu, M. and Lu, Y. (2025) Study on the Influence of Ultrasound Parameters on the Determination of Particle Size and Particle Size Distribution of Budesonide Suspension for Inhalation by Laser Diffraction Method. Herald of Medicine, 44, 1784-1788. (In Chinese)
[28]
Tinke, A.P., Vanhoutte, K., Vanhoutte, F., De Smet, M. and De Winter, H. (2005) Laser Diffraction and Image Analysis as a Supportive Analytical Tool in the Pharmaceutical Development of Immediate Release Direct Compression Formulations. International Journal of Pharmaceutics, 297, 80-88. https://doi.org/10.1016/j.ijpharm.2005.03.009
[29]
Silva, A.F.T., Burggraeve, A., Denon, Q., Van der Meeren, P., Sandler, N., Van Den Kerkhof, T., et al. (2013) Particle Sizing Measurements in Pharmaceutical Applications: Comparison of In-Process Methods versus Off-Line Methods. European Journal of Pharmaceutics andBiopharmaceutics, 85, 1006-1018. https://doi.org/10.1016/j.ejpb.2013.03.032
[30]
Vo, A., Feng, X., Smith, W.C., Zhu, D., Patel, M., Kozak, D., et al. (2021) Analyzing Ophthalmic Suspension Particle Size Distributions Using Laser Diffraction: Placebo Background Subtraction Method. InternationalJournalofPharmaceutics, 598, Article ID: 120401. https://doi.org/10.1016/j.ijpharm.2021.120401
[31]
Marriott, C., MacRitchie, H.B., Zeng, X.M. and Martin, G.P. (2006) Development of a Laser Diffraction Method for the Determination of the Particle Size of Aerosolised Powder Formulations: Comparison with Inertial Impaction. InternationalJournalofPharmaceutics, 326, 39-49. https://doi.org/10.1016/j.ijpharm.2006.07.021
[32]
Ransmark, E., ？kerfeldt, E., Liu, X., S？rensen, H., Gómez Galindo, F. and H？kansson, A. (2025) Evaluation of Laser Diffraction as a Fast Method for Particle Size Distribution Measurement of Plant Cell Structures in Whole Oat and Soy Beverages. FoodResearchInternational, 217, Article ID: 116781. https://doi.org/10.1016/j.foodres.2025.116781
[33]
Pei, Y., Hinchliffe, B.A. and Minelli, C. (2021) Measurement of the Size Distribution of Multimodal Colloidal Systems by Laser Diffraction. ACS Omega, 6, 14049-14058. https://doi.org/10.1021/acsomega.1c00411
[34]
U.S. Food and Drug Administration (2025) Inspection Observations (Form FDA 483). FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
[35]
U.S. Food and Drug Administration (2026) Warning Letters. FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
[36]
U.S. Food and Drug Administration (2017) Code of Federal Regulations, Title 21, Part 211.160: Current Good Manufacturing Practice for Finished Pharmaceuticals—General Requirements for Laboratory Controls. U.S. Government Publishing Office. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I/section-211.160
[37]
U.S. Food and Drug Administration (2017) Code of Federal Regulations, Title 21, Part 211.192: Current Good Manufacturing Practice for Finished Pharmaceuticals—Production Record Review. U.S. Government Publishing Office. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
[38]
U.S. Food and Drug Administration (2022) Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Revision 1). CDER. https://www.fda.gov/media/71001/download
[39]
Dubey, J., Jariwala, K.J., Srivastava, B.K., Koundinya, J., Rajyaguru, B. and Vaidya, F. (2026) A Quality by Design Approach to Development and Validation of a Laser-Based Analytical Method for Particle Size Distribution of Dapagliflozin Propanediol. JournalofAdvancesinMedicalandPharmaceuticalSciences, 28, 15-38. https://doi.org/10.9734/jamps/2026/v28i1839
[40]
Yang, S., Li, J., Zhang, Y. and Wang, X. (2025) Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications. Journal of Pharmaceutical Innovation, 20(2), 145-160.
[41]
Pharma Excipients (2020) De-Risking Excipient Particle Size Distribution Variability with Automated Robust Mixing: Integrating Quality by Design and Process Analytical Technology. European Journal of Pharmaceutics and Biopharmaceutics, 154, 123-134.
[42]
U.S. Food and Drug Administration (2004) PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. FDA Guidance. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance
[43]
Dahlgren, G., et al. (2020) Quality & Regulatory Solutions for PAT in Continuous Manufacturing. Pharmaceutical Engineering, 40, 30-38. https://ispe.org/pharmaceutical-engineering/september-october-2020/quality-regulatory-solutions-pat-continuous
[44]
U.S. Food and Drug Administration (2023) ICH Q13 Continuous Manufacturing of Drug Substances and Drug Products. U.S. FDA Guidance. https://www.fda.gov/media/165775/download
